Kiniksa Pharmaceuticals International (KNSA) Total Non-Current Liabilities (2018 - 2026)

Kiniksa Pharmaceuticals International (KNSA) has 9 years of Total Non-Current Liabilities data on file, last reported at $207.9 million in Q2 2026.

• Quarterly Total Non-Current Liabilities rose 32.55% year-over-year to $207.9 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $207.9 million (up 32.55% YoY) and the FY2025 annual result came in at $177.5 million, up 26.52% from the prior year.
• Total Non-Current Liabilities advanced to $207.9 million in Q2 2026, from $194.3 million in the prior quarter.
• In the past five years, Total Non-Current Liabilities ranged from a high of $207.9 million in Q2 2026 to a low of $50.9 million in Q1 2023.
• A 5-year average of $112.4 million and a median of $95.6 million in 2024 frame the typical range for Total Non-Current Liabilities.
• Annual changes were most pronounced in 2022 — Total Non-Current Liabilities soared 95.45% — and 2023, when it declined 21.05%.
• Tracing KNSA's Total Non-Current Liabilities over 5 years: stood at $61.7 million in 2022, then jumped by 38.81% to $85.6 million in 2023, then jumped by 63.85% to $140.3 million in 2024, then climbed by 26.52% to $177.5 million in 2025, then climbed by 17.15% to $207.9 million in 2026.
• The last three Total Non-Current Liabilities figures came in at $207.9 million (Q2 2026), $194.3 million (Q1 2026), and $177.5 million (Q4 2025), per Business Quant data.